Efficacy of Platinum Plus Cyclophosphamide in Patients with Epithelial Ovarian Cancer
Siriwan Tangjitgamol, MD*, Sumonmal Mamusirinitaya, MD*, Surawute Leelahakorn, MD*, Thaowalai Thawaramara, MD*, Kamol Pataradool, MD*, Pacheun Suekwatana, MD*, Kriengkrai Sittidilokratna, MD*
Affiliation : * Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Bangkok Metropolitan Administration Medical College and Vajira Hospital
Objectives : To determine the response rate (RR), 5-year progression-free survival (PFS), and the 5-year
survival rate (SVR) of epithelial ovarian cancer patients who received platinum plus cyclophosphamide as
adjuvant postoperative chemotherapy.
Materials and Methods : Epithelial ovarian cancer patients who underwent tumor debulking surgery and
received platinum plus cyclophosphamide as adjuvant chemotherapy at Vajira Hospital from January 1995 to
December 2003 were identified. All clinical and pathological data were reviewed.
Results : Among 114 patients included in the present study, 101 patients were evaluable for response. Overall
response rate was 79.2%. The 5-year PFS and 5-year SVR were 60.3% (95% confidence interval [95% CI];
50.5, 70.1%) and 60.7% (95% CI; 50.9, 70.5%) respectively. Subgroup analysis showed better RR, PFS, and
SVR in early stage than advanced stage disease.
Conclusion : The overall RR, 5-year PFS, and 5-year SVR of patients of the whole group were modest. These
outcomes were significantly better in the early stage than the advanced stage.
Keywords : Epithelial ovarian cancer, Response rate, Survival rate, Platinum, Cyclophosphamide.
